PortalPublikationenPrognostic role of thrombocytosis in recurrent ovarian cance...

Prognostic role of thrombocytosis in recurrent ovarian cancer

Standard

Prognostic role of thrombocytosis in recurrent ovarian cancer : a pooled analysis of the AGO Study Group. / Canzler, Ulrich; Lück, Hans-Joachim; Neuser, Petra; Sehouli, Jalid; Burges, Alexander; Harter, Philipp; Schmalfeldt, Barbara; Aminossadati, Behnaz; Mahner, Sven; Kommoss, Stefan; Wimberger, Pauline; Pfisterer, Jacobus; de Gregorio, Nikolaus; Hasenburg, Annette; Gropp-Meier, Martina; El-Balat, Ahmed; Jackisch, Christian; du Bois, Andreas; Meier, Werner; Wagner, Uwe.

in: ARCH GYNECOL OBSTET, Jahrgang 301, Nr. 5, 05.2020, S. 1267-1274.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Canzler, U, Lück, H-J, Neuser, P, Sehouli, J, Burges, A, Harter, P, Schmalfeldt, B, Aminossadati, B, Mahner, S, Kommoss, S, Wimberger, P, Pfisterer, J, de Gregorio, N, Hasenburg, A, Gropp-Meier, M, El-Balat, A, Jackisch, C, du Bois, A, Meier, W & Wagner, U 2020, 'Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group', ARCH GYNECOL OBSTET, Jg. 301, Nr. 5, S. 1267-1274. https://doi.org/10.1007/s00404-020-05529-y

APA

Canzler, U., Lück, H-J., Neuser, P., Sehouli, J., Burges, A., Harter, P., Schmalfeldt, B., Aminossadati, B., Mahner, S., Kommoss, S., Wimberger, P., Pfisterer, J., de Gregorio, N., Hasenburg, A., Gropp-Meier, M., El-Balat, A., Jackisch, C., du Bois, A., Meier, W., & Wagner, U. (2020). Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. ARCH GYNECOL OBSTET, 301(5), 1267-1274. https://doi.org/10.1007/s00404-020-05529-y

Vancouver

Canzler U, Lück H-J, Neuser P, Sehouli J, Burges A, Harter P et al. Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group. ARCH GYNECOL OBSTET. 2020 Mai;301(5):1267-1274. https://doi.org/10.1007/s00404-020-05529-y

Bibtex

@article{2c1fe7e60ced495c99dfc4308bc19c94,
title = "Prognostic role of thrombocytosis in recurrent ovarian cancer: a pooled analysis of the AGO Study Group",
abstract = "PURPOSE: Although thrombocytosis in patients with primary ovarian cancer has been widely investigated, there are only very few data about the role of thrombocytosis in recurrent ovarian cancer. The aim of our study was to investigate the impact of pretreatment thrombocytosis prior to chemotherapy on clinical outcome in patients with recurrent platinum eligible ovarian cancer.METHODS: In our retrospective analysis we included 300 patients who were treated by AGO Study Group Centers within three prospective, randomized phase-III-trials. All patients included had been treatment-free for at least 6 months after platinum-based chemotherapy. We excluded patients who underwent secondary cytoreductive surgery before randomization to the trial. Thrombocytosis was defined as a platelet count of ≥ 400⋅109/L.RESULTS: Pretreatment thrombocytosis was present in 37 out of 300 (12.3%) patients. Patients with thrombocytosis responded statistically significantly less to chemotherapy (overall response rate 35.3% and 41.6%, P = 0.046). The median progression-free survival (PFS) for patients with thrombocytosis was 6.36 months compared to 9.00 months for patients without thrombocytosis (hazard ratio [HR] = 1.19, 95% confidence interval [CI] = 0.84-1.69, P = 0.336). Median overall survival (OS) of patients with thrombocytosis was 16.33 months compared to 23.92 months of patients with a normal platelet count (HR = 1.46, 95% CI = 1.00-2.14, P = 0.047).CONCLUSIONS: The present analysis suggests that pretreatment thrombocytosis is associated with unfavorable outcome with regard to response to chemotherapy and overall survival in recurrent ovarian cancer.",
author = "Ulrich Canzler and Hans-Joachim L{\"u}ck and Petra Neuser and Jalid Sehouli and Alexander Burges and Philipp Harter and Barbara Schmalfeldt and Behnaz Aminossadati and Sven Mahner and Stefan Kommoss and Pauline Wimberger and Jacobus Pfisterer and {de Gregorio}, Nikolaus and Annette Hasenburg and Martina Gropp-Meier and Ahmed El-Balat and Christian Jackisch and {du Bois}, Andreas and Werner Meier and Uwe Wagner",
year = "2020",
month = may,
doi = "10.1007/s00404-020-05529-y",
language = "English",
volume = "301",
pages = "1267--1274",
journal = "ARCH GYNECOL OBSTET",
issn = "0932-0067",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Prognostic role of thrombocytosis in recurrent ovarian cancer

T2 - a pooled analysis of the AGO Study Group

AU - Canzler, Ulrich

AU - Lück, Hans-Joachim

AU - Neuser, Petra

AU - Sehouli, Jalid

AU - Burges, Alexander

AU - Harter, Philipp

AU - Schmalfeldt, Barbara

AU - Aminossadati, Behnaz

AU - Mahner, Sven

AU - Kommoss, Stefan

AU - Wimberger, Pauline

AU - Pfisterer, Jacobus

AU - de Gregorio, Nikolaus

AU - Hasenburg, Annette

AU - Gropp-Meier, Martina

AU - El-Balat, Ahmed

AU - Jackisch, Christian

AU - du Bois, Andreas

AU - Meier, Werner

AU - Wagner, Uwe

PY - 2020/5

Y1 - 2020/5

N2 - PURPOSE: Although thrombocytosis in patients with primary ovarian cancer has been widely investigated, there are only very few data about the role of thrombocytosis in recurrent ovarian cancer. The aim of our study was to investigate the impact of pretreatment thrombocytosis prior to chemotherapy on clinical outcome in patients with recurrent platinum eligible ovarian cancer.METHODS: In our retrospective analysis we included 300 patients who were treated by AGO Study Group Centers within three prospective, randomized phase-III-trials. All patients included had been treatment-free for at least 6 months after platinum-based chemotherapy. We excluded patients who underwent secondary cytoreductive surgery before randomization to the trial. Thrombocytosis was defined as a platelet count of ≥ 400⋅109/L.RESULTS: Pretreatment thrombocytosis was present in 37 out of 300 (12.3%) patients. Patients with thrombocytosis responded statistically significantly less to chemotherapy (overall response rate 35.3% and 41.6%, P = 0.046). The median progression-free survival (PFS) for patients with thrombocytosis was 6.36 months compared to 9.00 months for patients without thrombocytosis (hazard ratio [HR] = 1.19, 95% confidence interval [CI] = 0.84-1.69, P = 0.336). Median overall survival (OS) of patients with thrombocytosis was 16.33 months compared to 23.92 months of patients with a normal platelet count (HR = 1.46, 95% CI = 1.00-2.14, P = 0.047).CONCLUSIONS: The present analysis suggests that pretreatment thrombocytosis is associated with unfavorable outcome with regard to response to chemotherapy and overall survival in recurrent ovarian cancer.

AB - PURPOSE: Although thrombocytosis in patients with primary ovarian cancer has been widely investigated, there are only very few data about the role of thrombocytosis in recurrent ovarian cancer. The aim of our study was to investigate the impact of pretreatment thrombocytosis prior to chemotherapy on clinical outcome in patients with recurrent platinum eligible ovarian cancer.METHODS: In our retrospective analysis we included 300 patients who were treated by AGO Study Group Centers within three prospective, randomized phase-III-trials. All patients included had been treatment-free for at least 6 months after platinum-based chemotherapy. We excluded patients who underwent secondary cytoreductive surgery before randomization to the trial. Thrombocytosis was defined as a platelet count of ≥ 400⋅109/L.RESULTS: Pretreatment thrombocytosis was present in 37 out of 300 (12.3%) patients. Patients with thrombocytosis responded statistically significantly less to chemotherapy (overall response rate 35.3% and 41.6%, P = 0.046). The median progression-free survival (PFS) for patients with thrombocytosis was 6.36 months compared to 9.00 months for patients without thrombocytosis (hazard ratio [HR] = 1.19, 95% confidence interval [CI] = 0.84-1.69, P = 0.336). Median overall survival (OS) of patients with thrombocytosis was 16.33 months compared to 23.92 months of patients with a normal platelet count (HR = 1.46, 95% CI = 1.00-2.14, P = 0.047).CONCLUSIONS: The present analysis suggests that pretreatment thrombocytosis is associated with unfavorable outcome with regard to response to chemotherapy and overall survival in recurrent ovarian cancer.

U2 - 10.1007/s00404-020-05529-y

DO - 10.1007/s00404-020-05529-y

M3 - SCORING: Journal article

C2 - 32277253

VL - 301

SP - 1267

EP - 1274

JO - ARCH GYNECOL OBSTET

JF - ARCH GYNECOL OBSTET

SN - 0932-0067

IS - 5

ER -